Cargando…

Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer

Circulating fragments of type III collagen, measured by PRO-C3, has shown promising results as a tumor fibrosis biomarker. However, the fibrotic tumor microenvironment consists of many other collagens with diverse functions and unexplored biomarker potential. One example hereof is type XXII collagen...

Descripción completa

Detalles Bibliográficos
Autores principales: Madsen, Emilie A., Thorlacius-Ussing, Jeppe, Nissen, Neel I., Jensen, Christina, Chen, Inna M., Johansen, Julia S., Diab, Hadi M. H., Jørgensen, Lars N., Hansen, Carsten P., Karsdal, Morten A., Willumsen, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738409/
https://www.ncbi.nlm.nih.gov/pubmed/36497023
http://dx.doi.org/10.3390/cells11233763
_version_ 1784847535051898880
author Madsen, Emilie A.
Thorlacius-Ussing, Jeppe
Nissen, Neel I.
Jensen, Christina
Chen, Inna M.
Johansen, Julia S.
Diab, Hadi M. H.
Jørgensen, Lars N.
Hansen, Carsten P.
Karsdal, Morten A.
Willumsen, Nicholas
author_facet Madsen, Emilie A.
Thorlacius-Ussing, Jeppe
Nissen, Neel I.
Jensen, Christina
Chen, Inna M.
Johansen, Julia S.
Diab, Hadi M. H.
Jørgensen, Lars N.
Hansen, Carsten P.
Karsdal, Morten A.
Willumsen, Nicholas
author_sort Madsen, Emilie A.
collection PubMed
description Circulating fragments of type III collagen, measured by PRO-C3, has shown promising results as a tumor fibrosis biomarker. However, the fibrotic tumor microenvironment consists of many other collagens with diverse functions and unexplored biomarker potential. One example hereof is type XXII collagen (COL22). In this study, we investigated the biomarker potential of COL22 by measuring this in serum. An ELISA, named PRO-C22, was developed and measured in two serum cohorts consisting of patients with various solid tumors (n = 220) and healthy subjects (n = 33) (Cohort 1), and patients with pancreatic ductal adenocarcinoma (PDAC) (n = 34), and healthy subjects (n = 20) (Cohort 2). In Cohort 1, PRO-C22 was elevated in the serum from patients with solid tumors, compared to healthy subjects (p < 0.01 to p < 0.0001), and the diagnostic accuracy (AUROC) ranged from 0.87 to 0.98, p < 0.0001. In Cohort 2, the high levels of PRO-C22, in patients with PDAC, were predictive of a worse overall survival (HR = 4.52, 95% CI 1.90–10.7, p = 0.0006) and this remained significant after adjusting for PRO-C3 (HR = 4.27, 95% CI 1.24–10.4, p = 0.0013). In conclusion, PRO-C22 has diagnostic biomarker potential in various solid tumor types and prognostic biomarker potential in PDAC. Furthermore, PRO-C22 complemented PRO-C3 in predicting mortality, suggesting an additive prognostic value when quantifying different collagens.
format Online
Article
Text
id pubmed-9738409
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97384092022-12-11 Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer Madsen, Emilie A. Thorlacius-Ussing, Jeppe Nissen, Neel I. Jensen, Christina Chen, Inna M. Johansen, Julia S. Diab, Hadi M. H. Jørgensen, Lars N. Hansen, Carsten P. Karsdal, Morten A. Willumsen, Nicholas Cells Article Circulating fragments of type III collagen, measured by PRO-C3, has shown promising results as a tumor fibrosis biomarker. However, the fibrotic tumor microenvironment consists of many other collagens with diverse functions and unexplored biomarker potential. One example hereof is type XXII collagen (COL22). In this study, we investigated the biomarker potential of COL22 by measuring this in serum. An ELISA, named PRO-C22, was developed and measured in two serum cohorts consisting of patients with various solid tumors (n = 220) and healthy subjects (n = 33) (Cohort 1), and patients with pancreatic ductal adenocarcinoma (PDAC) (n = 34), and healthy subjects (n = 20) (Cohort 2). In Cohort 1, PRO-C22 was elevated in the serum from patients with solid tumors, compared to healthy subjects (p < 0.01 to p < 0.0001), and the diagnostic accuracy (AUROC) ranged from 0.87 to 0.98, p < 0.0001. In Cohort 2, the high levels of PRO-C22, in patients with PDAC, were predictive of a worse overall survival (HR = 4.52, 95% CI 1.90–10.7, p = 0.0006) and this remained significant after adjusting for PRO-C3 (HR = 4.27, 95% CI 1.24–10.4, p = 0.0013). In conclusion, PRO-C22 has diagnostic biomarker potential in various solid tumor types and prognostic biomarker potential in PDAC. Furthermore, PRO-C22 complemented PRO-C3 in predicting mortality, suggesting an additive prognostic value when quantifying different collagens. MDPI 2022-11-24 /pmc/articles/PMC9738409/ /pubmed/36497023 http://dx.doi.org/10.3390/cells11233763 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Madsen, Emilie A.
Thorlacius-Ussing, Jeppe
Nissen, Neel I.
Jensen, Christina
Chen, Inna M.
Johansen, Julia S.
Diab, Hadi M. H.
Jørgensen, Lars N.
Hansen, Carsten P.
Karsdal, Morten A.
Willumsen, Nicholas
Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title_full Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title_fullStr Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title_full_unstemmed Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title_short Type XXII Collagen Complements Fibrillar Collagens in the Serological Assessment of Tumor Fibrosis and the Outcome in Pancreatic Cancer
title_sort type xxii collagen complements fibrillar collagens in the serological assessment of tumor fibrosis and the outcome in pancreatic cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738409/
https://www.ncbi.nlm.nih.gov/pubmed/36497023
http://dx.doi.org/10.3390/cells11233763
work_keys_str_mv AT madsenemiliea typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT thorlaciusussingjeppe typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT nissenneeli typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT jensenchristina typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT cheninnam typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT johansenjulias typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT diabhadimh typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT jørgensenlarsn typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT hansencarstenp typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT karsdalmortena typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer
AT willumsennicholas typexxiicollagencomplementsfibrillarcollagensintheserologicalassessmentoftumorfibrosisandtheoutcomeinpancreaticcancer